Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study
- PMID: 26845268
- DOI: 10.4088/JCP.14m09580
Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study
Abstract
Objective: We investigated the relationship between antidepressant use and the risk of subsequent dementia development.
Method: A population-based retrospective case-control analysis was conducted using the Taiwan National Health Insurance Research Database. From patients enrolled in the National Health Insurance program between 2005 and 2011, we identified 2 subsets: 5,394 cases, who had major depression in 1997-2004 and subsequently were diagnosed with dementia (ICD-9-CM code 290) in 2005-2011, and 5,232 controls, who had major depression in 2005-2011 but no dementia history. The proportional distributions of antidepressant use and comorbidities in the dementia case and nondementia control groups were compared. Univariable and multivariable logistic regression analyses were used to estimate the odds ratios (ORs) and 95% CIs for the association between dementia and antidepressant use.
Results: The dementia patients were more likely to have diabetes, hypertension, stroke, and head injury. The adjusted OR for dementia was 0.24 (95% CI, 0.22-0.27) in patients using tricyclics . By contrast, the use of selective serotonin reuptake inhibitors (SSRIs) (OR = 2.48; 95% CI, 2.27-2.71), monoamine oxidase inhibitors (MAOIs) (OR = 1.86; 95% CI, 1.47-2.36), heterocyclic antidepressants (OR = 1.44; 95% CI, 1.32-1.57), and other antidepressants (OR = 2.05; 95% CI, 1.85-2.27) was associated with an increased risk of dementia. Furthermore, as the cumulative dose was increased, tricyclic antidepressants reduced the risk of dementia, whereas SSRIs, MAOIs, heterocyclic antidepressants, and other antidepressants increased the risk of dementia.
Conclusions: The incidence of dementia in patients is associated with antidepressant medication use. Treatment with tricyclic antidepressants was associated with a reduced risk of dementia, whereas treatment with SSRIs, MAOIs, heterocyclic antidepressants, and other antidepressants was associated with an increased risk of dementia.
© Copyright 2016 Physicians Postgraduate Press, Inc.
Comment in
-
Antidepressants and Risk of Dementia: Methodology Is Essential.J Clin Psychiatry. 2016 Sep;77(9):e1151. doi: 10.4088/JCP.16lr10742. J Clin Psychiatry. 2016. PMID: 27780325 No abstract available.
-
Dr Kao Replies.J Clin Psychiatry. 2016 Sep;77(9):e1152. doi: 10.4088/JCP.16lr10742a. J Clin Psychiatry. 2016. PMID: 27780326 No abstract available.
Similar articles
-
Antidepressants and risk of dementia in migraine patients: A population-based case-control study.Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jul 3;77:83-89. doi: 10.1016/j.pnpbp.2017.04.006. Epub 2017 Apr 7. Prog Neuropsychopharmacol Biol Psychiatry. 2017. PMID: 28392483
-
Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.Clin Ther. 2012 Jan;34(1):113-23. doi: 10.1016/j.clinthera.2011.11.024. Epub 2011 Dec 16. Clin Ther. 2012. PMID: 22177545
-
Risk analysis of use of different classes of antidepressants on subsequent dementia: A nationwide cohort study in Taiwan.PLoS One. 2017 Apr 6;12(4):e0175187. doi: 10.1371/journal.pone.0175187. eCollection 2017. PLoS One. 2017. PMID: 28384235 Free PMC article.
-
Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.Pharmacotherapy. 2015 Apr;35(4):433-49. doi: 10.1002/phar.1576. Pharmacotherapy. 2015. PMID: 25884531 Review.
-
[Antidepressive agents and hyponatremia: A literature review and a case/non-case study in the French Pharmacovigilance database].Therapie. 2018 Oct;73(5):389-398. doi: 10.1016/j.therap.2018.02.006. Epub 2018 Mar 1. Therapie. 2018. PMID: 29773358 Review. French.
Cited by
-
Identifying individuals at high risk for dementia in primary care: Development and validation of the DemRisk risk prediction model using routinely collected patient data.PLoS One. 2024 Oct 4;19(10):e0310712. doi: 10.1371/journal.pone.0310712. eCollection 2024. PLoS One. 2024. PMID: 39365767 Free PMC article.
-
Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress.Front Pharmacol. 2020 Jul 31;11:1168. doi: 10.3389/fphar.2020.01168. eCollection 2020. Front Pharmacol. 2020. PMID: 32848775 Free PMC article. Review.
-
Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study.Alzheimers Dement (N Y). 2020 Nov 26;6(1):e12095. doi: 10.1002/trc2.12095. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 33304987 Free PMC article.
-
Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study.Alzheimers Dement. 2024 Aug;20(8):5528-5539. doi: 10.1002/alz.14048. Epub 2024 Jul 3. Alzheimers Dement. 2024. PMID: 38958394 Free PMC article.
-
Drug-Induced Cognitive Impairment.Drug Saf. 2025 Apr;48(4):339-361. doi: 10.1007/s40264-024-01506-5. Epub 2024 Dec 24. Drug Saf. 2025. PMID: 39718691 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical